Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KOSDAQ - Delayed Quote KRW

HLB Genex, Inc. (187420.KQ)

Compare
3,450.00
+115.00
+(3.45%)
At close: 3:30:30 PM GMT+9
Loading Chart for 187420.KQ
  • Previous Close 3,335.00
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 5,930.00
  • Volume 0
  • Avg. Volume 129,591
  • Market Cap (intraday) 83.447B
  • Beta (5Y Monthly) 0.29
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications. The company was formerly known as GenoFocus, Inc. HLB Genex, Inc. was founded in 2000 and is based in Daejeon, South Korea.

hlbgenex.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 187420.KQ

View More

Performance Overview: 187420.KQ

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

187420.KQ
22.65%
KOSPI Composite Index (^KS11)
3.25%

1-Year Return

187420.KQ
10.62%
KOSPI Composite Index (^KS11)
7.23%

3-Year Return

187420.KQ
43.07%
KOSPI Composite Index (^KS11)
8.11%

5-Year Return

187420.KQ
28.42%
KOSPI Composite Index (^KS11)
33.40%

Compare To: 187420.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 187420.KQ

View More

Valuation Measures

Annual
As of 4/14/2025
  • Market Cap

    80.67B

  • Enterprise Value

    41.43B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.22

  • Price/Book (mrq)

    3.39

  • Enterprise Value/Revenue

    1.17

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -53.14%

  • Return on Assets (ttm)

    -0.94%

  • Return on Equity (ttm)

    -62.19%

  • Revenue (ttm)

    35.43B

  • Net Income Avi to Common (ttm)

    -18.83B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    83.81B

  • Total Debt/Equity (mrq)

    157.94%

  • Levered Free Cash Flow (ttm)

    47.36B

Research Analysis: 187420.KQ

View More

Company Insights: 187420.KQ

Research Reports: 187420.KQ

View More

People Also Watch